Objective: To determine antioxidant status of serum bilirubin, uric acid and albumin in pemphigus vulgaris. Study Design: Cross sectional study Place of Study and Duration: This study was done at Department of Dermatology Mayo Hospital Lahore from July 11, 2019 to January 11, 2020. Methodology: All 60 cases meeting inclusion criteria was enrolled after taking informed consent, from outdoor Department of Dermatology Mayo Hospital Lahore. A total of 200 cases meeting inclusion criteria was taken after getting approval from CPSP. A brief demographic information and contact detail was taken. Venous blood was collected from each subject for the evaluation of Serum Bilirubin, Uric Acid and Albumin. Total bilirubin, direct bilirubin, indirect bilirubin, UA and albumin levels was determined using an automatic biochemical analyzer (Model 7600‐120; Hitachi High Technologies, Tokyo, Japan). All the values was recorded as per operational definition. Results: The mean age of patients was 40.08±12.89 years with minimum and maximum age as 18 and 60 years. There were 22(36.7%) male and 38(63.3%) female cases with higher female to male ratio. The mean BMI was 29.08±2.70 with minimum and maximum BMI as 24 and 33.90. The mean serum bilirubin level was 8.51±1.64µmol/L with minimum and maximum serum bilirubin was 5.80µmol/L and 11µmol/L. The mean uric acid levels in this study was 234.37±33.46µmol/L with minimum and maximum value as 160.00µmol/L and 280.00µmol/L. The mean Albumin level in this study was 34.20 ±3.69g/l with minimum and maximum albumin level as 29.00g/l and 41g/l. Conclusion: It is concluded that oxidative stress and antioxidant status are important in the pathogenic mechanism of PV. Hence by keeping these profile in mind that it can be of benefit to administer bilirubin, UA and albumin or their precursors as a replacement therapy to patients with PV who have low antioxidant status. Key Words: Antioxidant status, serum bilirubin, uric acid, albumin, pemphigus vulgaris.

Aim: To find clinical efficacy of oral administration of finasteride at a dose of 2.5mg/day in women with female pattern hair loss. Study design: Descriptive cases series Place and duration of study: Department of Dermatology, Unit II, Mayo Hospital Lahore from 01-10-2019 to 31-03-2020. Methodology: A total of 137 cases were taken. Trichoscopy was performed at enrollment and after 5 months. At the standardized resolution of each image, ratio of terminal to vellus hair measured at two sites of the scalp. Clinical efficacy was determined as per operational definition at 5th month of treatment. Results: Patients ranged between 40-70 years of age with mean age of 49.5±6.9 years. Pre-menopause women were 99 (72.3%) while post-menopause were 38(27.7%). Mean duration of FPHL was observed 4.4±1.3 months. Out of 137 cases, 92 women (67.2%) belonged to Ludwig scale-I and remaining 45 women (32.8%) belonged to Ludwig scale-II. Clinical efficacy of finasteride 2.5mg/day was found in 85 women (62%). Stratification for age, duration of FPHL, menopause status, and baseline Ludwig scale was also carried out. Four to six months duration of FPHL, premenopausal women and lower Ludwig scale showed significant effect of finasteride (p <0.001, p=0.010 and p 0.003, respectively). Conclusion: In conclusion, the efficacy of administration of finasteride at a dose of 2.5 mg/day for patients with female pattern hair loss was recorded 62%, and it was also observed that finasteride revealed better effect on hair growth in patients having lower Ludwig score. Keywords: Female pattern hair loss; Finasteride, Efficacy, Oral administration.

Aim: To compare the outcome of 35% glycolic acid and 30% salicylic acid in patients with acne vulgaris. Study design: It was a randomized controlled trial. Plate and duration of study: Department of Dermatology at Mayo Hospital, Lahore from 31-08-2019 to 29-02-2020. Methodology: This study involved 120 patients of both genders with ages between 15 to 40 years, who presented with mild to moderate acne. These patients were randomly allocated into two treatment groups. Patients in Group-A were treated with 35.0% glycolic acid while those in Group-B with 30.0% salicylic acid. Outcome variable was mean of percentage reduction in acne severity index one month after treatment, which was noted and compared between the groups. A written informed consent was taken from each patient. Results: The mean age of the patients was 21.56±5.09 years. There was a female predominance with male to female ratio of 1:1.2. Majority (67.5%) of the patients had Fitz Patrick Type-V skin phototype while 39 (32.5%) patients had Type-IV phototype skin. The severity of acne was mild in 75 (62.5%) patients and moderate in 45 (37.5%) patients. There was no statistically significant difference in the mean acne severity index between patients treated with 30.0% salicylic acid versus 35.0% glycolic acid (16.52±3.69 vs.16.48±4.01 p 0.962) at baseline. Conclusion: Chemical peeling with 30.0% salicylic acid was found superior to 35.0% glycolic acid in patients with mild to moderate acne regardless of patients’ age, gender, BMI, skin phototype and severity of disease which advocates the preferred use of salicylic acid peeling in the management of patients with acne in future dermatologic practice. Keywords: Acne, Chemical Peeling, Salicylic Acid, Glycolic Acid